

Advancing Structured Benefit-Risk Assessment in FDA Review

The Duke-Margolis Center for Health Policy • Washington, DC

October 4, 2017

Participant List**Steven Anderson**

Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Meghana Chalasani

Operations Research Analyst, Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Victor Crentsil

Associate Director for Regulatory Science, Office of Drug Evaluation III, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gerald Dal Pan

Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Alex Davis

Assistant Professor, Department of Engineering and Public Policy, Carnegie Mellon University

Gregory Daniel

Deputy Director, Duke-Margolis Center for Health Policy, Duke University

Sara Eggers

Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Baruch Fischhoff

Howard Heinz University Professor, Department of Engineering and Public Policy, Institute for Politics and Strategy, Carnegie Mellon University

Richard Forshee

Associate Director for Research, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Meredith Freed

Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

C. Bernie Good

Chair, Medical Advisory Panel, Pharmacy Benefits Management, Department of Veterans Affairs, and Professor, Medicine and Pharmacy, University of Pittsburgh

George Gray

Professor and Interim Chair, Department of Environmental and Occupational Health, Milken Institute of Public Health, George Washington University

Tarek Hammad

Head of Signal Detection and Benefit Risk Assessment, Global Drug Safety Innovation, EMD Serono, Inc.

Brett Hauber

Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions

Weili He

Head of Global Medical Affairs Statistics, AbbVie

Telba Irony

Deputy Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Laura Lee Johnson

Director (Acting), Division of Biometrics III, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Reza Kazemi

Operations Research Analyst, Performance Analysis and Data Services Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Anne Khademian

Director and Professor, School of Public and International Affairs, Virginia Tech

Andrew Kish

Director, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lisa LaVange

Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kerry Jo Lee

Medical Officer, Guidance and Policy Team, Immediate Office, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Bennett Levitan

Senior Director, Benefit-risk Assessment, Department of Epidemiology, Janssen Research & Development

Megan Moncur

Senior Advisor, Science of Patient Input, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Theresa Mullin

Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Rebecca Noel

Global Benefit-Risk Leader, Global Patient Safety, Eli Lilly and Company

Thomas Permutt

Director, Division of Biometrics II, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lawrence Phillips

Emeritus Professor of Decision Sciences, London School of Economics and Political Science

Claudia Prada

Senior Medical Director, Biogen

Elizabeth Richardson

Managing Associate, Duke-Margolis Center for Health Policy, Duke University

Frank Rockhold

Professor of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Duke University Medical Center

James Smith

Deputy Director, Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Steve Snapinn

Vice President, Global Biostatistical Science, Amgen

Peter Stein

Deputy Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Graham Thompson

Operations Research Analyst, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Robert Temple

Deputy Center Director for Clinical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Ellis Unger

Director, Office of New Drugs, Office of Drug Evaluation I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Pujita Vaidya

Director (Acting), Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Celia Witten

Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Shanon Woodward

Operations Research Analyst, Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Hong Yang

Biologist, Analytics and Benefit Risk Assessment Team, Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, U.S. Food and Drug Administration